These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 28123155)

  • 1. Rivaroxaban-induced chest wall spontaneous expanding hematoma.
    Salemis NS
    Drug Discov Ther; 2017 Mar; 11(1):47-50. PubMed ID: 28123155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spontaneous rectus sheath hematoma during rivaroxaban therapy.
    Kocayigit I; Can Y; Sahinkus S; Aydın E; Vatan MB; Kılıc H; Gunduz H
    Indian J Pharmacol; 2014; 46(3):339-40. PubMed ID: 24987185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated hemopericardium associated with rivaroxaban: first case report.
    Shivamurthy P; Brar N; Therrien ML
    Pharmacotherapy; 2014 Sep; 34(9):e169-72. PubMed ID: 25074401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of rivaroxaban anticoagulation by nonactivated prothrombin complex concentrate in urgent surgery.
    Chic Acevedo C; Velasco F; Herrera C
    Future Cardiol; 2015 Sep; 11(5):525-9. PubMed ID: 26090568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attempted suicide with rivaroxaban.
    Blickstein D; Younes S; Nakav S
    Ann Hematol; 2016 Dec; 95(12):2093-2094. PubMed ID: 27637914
    [No Abstract]   [Full Text] [Related]  

  • 6. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spontaneous chest wall hematoma with dual antiplatelet therapy.
    Bevan P; Menon A; Bunton R
    Can J Cardiol; 2014 Feb; 30(2):247.e1-2. PubMed ID: 24290862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
    Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombocytopenia due to rivaroxaban: A rare adverse effect.
    Tığlıoğlu M; Akyol P; Sağlam B; Aras MR; Afacan Öztürk HB; Yıldız A; Albayrak M
    Transfus Apher Sci; 2020 Dec; 59(6):102883. PubMed ID: 32807650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tympanic Membrane Haematoma in a RivaroxabanTreated Patient: A Case Report.
    Saldanha I; Matos R; Órfão T; Santos M
    Acta Med Port; 2019 Jun; 32(6):469-470. PubMed ID: 31292030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is anti-factor Xa chromogenic assay for Rivaroxaban appropriate in clinical practice? Advantages and comparative drawbacks.
    Bardy G; Fischer F; Appert A; Baldin B; Stève M; Spreux A; Lavrut T; Drici MD
    Thromb Res; 2015 Aug; 136(2):396-401. PubMed ID: 26058941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nontraumatic spinal subdural hematoma complicating direct factor Xa inhibitor treatment (rivaroxaban): a challenging management.
    Dargazanli C; Lonjon N; Gras-Combe G
    Eur Spine J; 2016 May; 25 Suppl 1():100-3. PubMed ID: 26228186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.
    Spiller HA; Mowry JB; Aleguas A; Griffith JR; Goetz R; Ryan ML; Bangh S; Klein-Schwartz W; Schaeffer S; Casavant MJ
    Ann Emerg Med; 2016 Feb; 67(2):189-95. PubMed ID: 26298448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure.
    Flierl U; Fraccarollo D; Micka J; Bauersachs J; Schäfer A
    Pharmacol Res; 2013 Aug; 74():49-55. PubMed ID: 23714416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
    Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
    Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors.
    Grandhi R; Newman WC; Zhang X; Harrison G; Moran C; Okonkwo DO; Ducruet AF
    World Neurosurg; 2015 Dec; 84(6):1956-61. PubMed ID: 26341438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of activated charcoal and lipid emulsion treatment in model of acute rivaroxaban toxicity.
    Uzunget SC; Evrin T; Uzunget SB; Ertürk ZK; Akıncıoğlu E; Özdemir S; Korkmaz A
    Am J Emerg Med; 2018 Aug; 36(8):1346-1349. PubMed ID: 29395759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
    Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban for the treatment and prevention of thromboembolic disease.
    Antoniou S
    J Pharm Pharmacol; 2015 Aug; 67(8):1119-32. PubMed ID: 26059702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.